

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

**(1) RESIGNATION OF EXECUTIVE DIRECTOR;
(2) CHANGE OF AUTHORISED REPRESENTATIVE AND
COMPLIANCE OFFICER;
AND
(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces the following (1) resignation of the executive Director; (2) change of the Authorised Representative and Compliance Officer; and (3) change in composition of the Board committees, all with effect from 29 December 2023:

1. Mr. CHAU Wai Wah Fred has tendered his resignation as the executive Director, Authorised Representative, Compliance Officer, member of the Remuneration Committee and Nomination Committee;
2. Ms. KWOK Shuk Yi, the executive Director, has been appointed as an Authorised Representative and a member of the Nomination Committee;
3. Mr. HO Kam Kin, the executive Director, has been appointed as the Compliance Officer; and
4. Mr. HEUNG Pik Lun, the independent non-executive Director, has been appointed as a member of the Remuneration Committee.

(1) RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) hereby announces that with effect from 29 December 2023:

Mr. CHAU Wai Wah Fred (“**Mr. CHAU**”) has tendered his resignation as the executive Director due to his other personal engagements. Mr. CHAU has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. CHAU for his valuable contribution to the Company during his tenure of office.

(2) CHANGE OF AUTHORISED REPRESENTATIVE AND COMPLIANCE OFFICER

The Board also announces that following the resignation of Mr. CHAU as the executive Director, with effect from 29 December 2023:

Mr. CHAU has ceased to act as the authorised representative (the “**Authorised Representative**”) and the compliance officer (the “**Compliance Officer**”) of the Company. In replacement of Mr. CHAU, Ms. KWOK Shuk Yi (“**Ms. KWOK**”), the executive Director, and Mr. HO Kam Kin (“**Mr. HO**”), the executive Director, have been appointed as the Authorised Representative and Compliance Officer respectively for the purpose of Rules 5.24 and 5.19 respectively of the Rules Governing the Listing of Securities on GEM (“**GEM**”) of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that with effect from 29 December 2023:

Mr. CHAU has resigned as the member of the remuneration committee of the Company (the “**Remuneration Committee**”) and nomination committee of the Company (the “**Nomination Committee**”);

Mr. HEUNG Pik Lun (“**Mr. HEUNG**”), the independent non-executive Director, has been appointed as a member of the Remuneration Committee; and

Ms. KWOK, the executive Director, has been appointed as a member of the Nomination Committee.

The Board would like to take this opportunity to express its warmest welcome to Ms. KWOK, Mr. HO and Mr. HEUNG for their new roles in the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 29 December 2023

As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.